⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033589 | 0.90 | — | — | |
| SCHEMBL11118877 | 0.73 | GABRA1 (0.33) | — | |
| SCHEMBL454358 | 0.60 | — | — | |
| SCHEMBL900222 | 0.59 | G6PD (0.33) | — | |
| SCHEMBL1598988 | 0.59 | — | — | |
| Benzene SCHEMBL27282100 | 0.57 | TP53 (0.43) | — | |
| Benzene SCHEMBL5194700 | 0.50 | TP53 (0.33) | — | |
| Benzene SCHEMBL6360513 | 0.50 | TP53 (0.33) | — | |
| Benzene SCHEMBL28927988 | 0.50 | TP53 (0.33) | — | |
| Benzene SCHEMBL28112029 | 0.50 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2087115-B1 | BLOCKING OF GENE EXPRESSION IN EUKARYOTIC CELLS | NOVARX (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20100144831-A1 | BLOCKING OF GENE EXPRESSION IN EUKARYOTIC CELLS | NOVARX CORPORATION | 2010-06-10 | — | — | US | disclosed |
| EP-2087115-A2 | BLOCKING OF GENE EXPRESSION IN EUKARYOTIC CELLS | Novarx (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008039937-A2 | BLOCKING OF GENE EXPRESSION IN EUKARYOTIC CELLS | NOVARX (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2001051630-A1 | ANTISENSE COMPOSITIONS AND METHODS | BAYLOR UNIVERSITY (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6248724-B1 | HYPOTENSIVE AGENTS | UNIVERSITY OF FLORIDA | 2001-06-19 | — | — | US | disclosed |
| WO-2000015783-A9 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE | UNIV FLORIDA (US) | 2000-08-24 | — | — | WO | disclosed |
| US-6087343-A | CONTROLLING HYPERTENSION AND CARDIOVASCULAR DISEASE FOR PROLONGED PERIODS WITH SINGLE DOSES | UNIVERSITY OF FLORIDA (US) | 2000-07-11 | — | — | US | disclosed |
| WO-2000015783-A2 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE | UNIVERSITY OF FLORIDA (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0906123-A4 | OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA | UNIV FLORIDA (US) | 1999-05-26 | — | — | EP | disclosed |
| EP-0906123-A1 | OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA | University of Florida (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999015643-A2 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | UNIVERSITY OF FLORIDA (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1997033623-A1 | OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA | UNIVERSITY OF FLORIDA (US) | 1997-09-18 | — | — | WO | disclosed |
| US-5135917-A | Bind to sense DNA strand coding for receptors | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1992000990-A1 | INTERLEUKIN RECEPTOR EXPRESSION INHIBITING ANTISENSE OLIGONUCLEOTIDES | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |